Central Nervous System

Current pipeline developments could bring new hope for patients with PPMS

Multiple sclerosis (MS) is an autoimmune disease causing chronic inflammation and demyelination of the nerves, affecting around 2.5 million people…

NRG raises Series A funds for Parkinson’s and ALS therapy development

NRG Therapeutics has raised Series A funds worth $18.3m (£16m) to progress the development of mitochondrial therapeutics to treat neurodegenerative ailments such…

NKGen and Parkinson’s Foundation partner to advance cell therapy

NKGen Biotech and the Parkinson’s Foundation have entered a partnership to progress the former’s new natural killer (NK) cell therapy development for…

Reaction Biology to acquire Vyant Bio subsidiary’s operations in US

Reaction Biology (Reaction) has concluded a definitive agreement for the acquisition of the US operations of Vyant Bio subsidiary, vivoPharm.…

Emalex raises $250m for Tourette syndrome drug development

Emalex Biosciences has raised Series D funds worth $250m led by Bain Capital Life Sciences to progress the development of…

Novel CSF biomarkers signal new avenues for Parkinson’s therapeutics

Last week, Nature magazine published a paper detailing an in-situ study of Parkinson’s disease (PD), showing protein structural changes in…

Stalicla signs licence deal for Evgen Pharma’s lead asset SFX-01

Swiss biotech company Stalicla has signed a licensing deal with Evgen Pharma for the latter’s lead asset, SFX-01, in neurodevelopmental…

Pfizer acquires biopharma firm Biohaven for $11.6bn

Pfizer has acquired commercial-stage biopharmaceutical firm Biohaven Pharmaceutical for $148.50 for each share or a total consideration of nearly $11.6bn in cash. In…

FDA grants approval for Amylyx’s Relyvrio to treat ALS

The US Food and Drug Administration (FDA) has granted approval for Amylyx Pharmaceuticals’ Relyvrio (sodium phenylbutyrate and taurursodiol) to treat adult patients…

EC approves Alexion’s Ultomiris for generalised myasthenia gravis

The European Commission (EC) has granted approval for AstraZeneca division Alexion’s Ultomiris (ravulizumab) as an add-on to standard therapy to…

FDA approves bluebird bio’s Skysona to treat cerebral adrenoleukodystrophy

The US Food and Drug Administration (FDA) has awarded Accelerated Approval for bluebird bio’s Skysona (elivaldogene autotemcel; eli-cel) for slowing neurologic dysfunction…

University of Birmingham scientists detect new drug target for CNS injury

Scientists at the University of Birmingham in the UK have detected a possible drug target for the treatment of neurological…

FDA and NIH partner for neurodegenerative disease treatment development

The US Food and Drug Administration (FDA) and the US National Institutes of Health (NIH) have unveiled a public-private partnership (PPP) to…

Rare Disease Spotlight- Oncology therapies dominate the orphan drug landscape

Rare diseases affect only a small percentage of the population, and since their pathophysiology has historically been poorly studied, there…

A tough puzzle: complexity slows drug development for concussions

Last month saw two companies announce positive results from early-stage studies endeavoring to find a treatment for concussions, an area…